What is it about?
Just a few injections of the vaccine can inhibit tumor growth and prevent its recurrence with fewer toxic side effects, and our neoantigen therapeutic vaccine based on yeast-derived beta-glucan particles has got encouraging complete tumor remission and long-term immune memory in multiple mouse models.
Featured Image
Photo by CDC on Unsplash
Why is it important?
We propose a safe and broad-spectrum peptide neoantigen vaccine system (GP-Neoantigen) based on β-1,3-glucan particles (GPs) derived from natural edible Saccharomyces cerevisiae. The ideal particle size and act as the ligand of the dectin-1 receptor endowed it high target specificity for uptake by antigen-presenting cells. The encouraging curative effect, uniform size and high degree of consistency from batch to batch provide broad possibilities for its further clinical promotion and the development of personalized vaccine therapy.
Perspectives
Neoantigen therapeutic vaccine must be a panacea in the process of human beings fighting against tumors in the future, though it has not yet entered the first-line clinical treatment regimen. It can be used synergistically with any other tumor treatment regimens, and has an excellent effect in controlling tumor progression and preventing recurrence. Perhaps half a century later, when the vast majority of cancer patients can easily afford its cost, the era of cancer therapeutic vaccines will come. Let's wait and see.
ZHE JING
Read the Original
This page is a summary of: A Potent Micron Neoantigen Tumor Vaccine GP‐Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models, Advanced Science, June 2022, Wiley,
DOI: 10.1002/advs.202201496.
You can read the full text:
Resources
Contributors
The following have contributed to this page
